Abstract Library

#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)

Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Raymond E, Harmon C, Niccoli P, Metrakos P, Borbath I,

Keywords: Sunitinib, phase 3, pancreatic neuroendocrine tumor, Ki-67 index, prior treatment, prognostic factor,

#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis

Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Metrakos P

Authors: Metrakos P, Hassanain M, Caberera T, CHaudhury P, Dumitra S,

Keywords: radio-embolization (TheraSphere ®) treatment, neuroendocrine liver metastasis, response rate, disease bulk,